Last reviewed · How we verify
SADBE
At a glance
| Generic name | SADBE |
|---|---|
| Also known as | Squaric acid dibutyl ester |
| Sponsor | Squarex, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2, PHASE3)
- Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata (EARLY_PHASE1)
- Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1) (PHASE1)
- Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis (PHASE1, PHASE2)
- SADBE for Congenital Melanocytic Nevi (EARLY_PHASE1)
- A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis (PHASE2)
- Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SADBE CI brief — competitive landscape report
- SADBE updates RSS · CI watch RSS
- Squarex, LLC portfolio CI